Please assess the completion status of the following clinical trial:

Trial Title: Effect of Vilanterol on Methacholine Challenge Results

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* men and women aged 18 or older~* stable mild-to-moderate asthma~* baseline methacholine PC20 less than or equal to 8mg/mL~* FEV1 greater than or equal to 65% of predicted~Exclusion Criteria:~* Use of long-acting anticholinergic or long-acting beta2 agonist within 30 days of study~* pregnant or nursing~* diabetes~* hypokalemia~* cardiovascular, prostate, kidney, or urinary retention problems~* lactose-intolerant~* allergy-induced asthma symptoms or upper respiratory tract infection within four weeks of study~* current smokers~* past smokers with smoking history \>10 pack years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vilanterol (Type: EXPERIMENTAL): Vilanterol (25mcg)+ fluticasone (100mcg) inhaled through Ellipta® inhaler
- Fluticasone (Type: EXPERIMENTAL): Fluticasone (100mcg) monotherapy inhaled through Ellipta® inhaler
- Placebo (Type: PLACEBO_COMPARATOR): Lactose powder inhaled through Ellipta® inhaler

Based on this trial design, predict the completion outcome and termination type (if applicable).